The Chronic Cough market report also offers comprehensive insights into the Chronic Cough market size, share, Chronic Cough epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Cough market size growth forward.
Some of the key highlights from the Chronic Cough Market Insights Report:
Several key pharmaceutical companies, includingMerck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others, are developing novel products to improve the Chronic Cough treatment outlook.
Gefapixant is an oral, non-narcotic medication that acts as a selective P2X₃ receptor antagonist. By inhibiting these receptors, gefapixant aims to reduce sensory nerve activation and, consequently, the cough reflex. Clinical trials have demonstrated its effectiveness in decreasing cough frequency. As a result, gefapixant received approval in Japan in 2022 and in the European Union in 2023 for treating adults with refractory or unexplained chronic cough.
In the United States, Merck submitted a New Drug Application (NDA) for gefapixant to the U.S. Food and Drug Administration (FDA). However, in January 2022, the FDA issued a Complete Response Letter (CRL) requesting additional data related to the measurement of efficacy, indicating that the existing data were insufficient to support approval at that time.
Subsequently, in November 2023, the FDA’s Pulmonary-Allergy Drug Advisory Committee voted 12-to-1 against approving gefapixant for adults with unexplained chronic cough. The panel expressed concerns over the modest reduction in cough frequency observed in clinical trials and questioned the clinical significance of the findings.
Originally developed by Algernon Pharmaceuticals, ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist. In March 2024, Seyltx acquired ifenprodil, following Phase II trials that demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough.
Developed by Trevi Therapeutics, Haduvio is an extended-release formulation of nalbuphine. A Phase IIb clinical trial is underway to assess its efficacy in IPF patients with chronic cough, following a Phase IIa trial that showed a significant reduction in daytime cough frequency.
NeRRe Therapeutics is developing orvepitant maleate, which is currently in clinical trials for treating refractory chronic cough.
Chronic refractory cough therapies are MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others.
As per DelveInsight analysis, the Chronic Cough market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Chronic Cough Market Landscape
Chronic Cough Overview
Chronic cough is a persistent cough that lasts eight weeks or longer in adults (or four weeks in children). It is not a disease itself but a symptom of an underlying condition.
Do you know the treatment paradigms for different countries? Download our Chronic Cough Market Sample Report
Chronic Cough Epidemiology Segmentation
DelveInsight’s Chronic Cough market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Chronic Cough historical patient pools and forecasted Chronic Cough patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Cough Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Chronic Cough Prevalence
Age-Specific Chronic Cough Prevalence
Gender-Specific Chronic Cough Prevalence
Diagnosed and Treatable Cases of Chronic Cough
Visit for more @ Chronic Cough Epidemiological Insights
Chronic Cough Market Outlook
Chronic cough, defined as a cough lasting more than eight weeks, has garnered significant attention due to its impact on patient quality of life and the healthcare system. The market for chronic cough treatments is experiencing notable growth, driven by advancements in therapeutic options and a deeper understanding of the condition’s underlying causes.
Sanofi and Regeneron’s Dupixent received FDA approval in September 2024 for use as an add-on treatment in adults with inadequately controlled chronic obstructive pulmonary disease (COPD), commonly referred to as “smoker’s lung.” This approval expands the therapeutic options available for managing chronic respiratory conditions associated with chronic cough.
North America currently holds the largest share of the chronic cough market, attributed to a high prevalence of respiratory conditions and advanced healthcare infrastructure. Other regions, including Asia-Pacific and Europe, are also experiencing growth due to increasing awareness and improved diagnostic capabilities.
The chronic cough market is poised for substantial growth in the coming years, driven by increasing disease prevalence, environmental factors, and advancements in therapeutic options. Ongoing research and development, coupled with strategic collaborations among pharmaceutical companies, are expected to further enhance the treatment landscape for chronic cough.
Chronic Cough Key Companies
Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others
For more information, visit Chronic Cough Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Chronic Cough Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Chronic Cough, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Chronic Cough epidemiology in the 7MM
Chronic Cough marketed and emerging therapies
Chronic Cough companies
Chronic Cough market drivers and barriers
Table of Contents:
1 Chronic Cough Market Key Comprehensive Insights
2 Chronic Cough Market Report Introduction
3 Competitive Intelligence Analysis for Chronic Cough
4 Chronic Cough Market Analysis Overview at a Glance
5 Executive Summary of Chronic Cough
6 Chronic Cough Epidemiology and Market Methodology
7 Chronic Cough Epidemiology and Patient Population
8 Chronic Cough Patient Journey
9 Chronic Cough Treatment Algorithm, Chronic Cough Current Treatment, and Medical Practices
10 Key Endpoints in Chronic Cough Clinical Trials
11 Chronic Cough Marketed Therapies
12 Chronic Cough Emerging Therapies
13 Chronic Cough: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Chronic Cough
16 Chronic Cough Market Key Opinion Leaders Reviews
18 Chronic Cough Market Drivers
19 Chronic Cough Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Chronic Cough Epidemiology 2034
DelveInsight’s “Chronic Cough – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Chronic Cough epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Cough Pipeline 2024
“Chronic Cough Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Cough market. A detailed picture of the Chronic Cough pipeline landscape is provided, which includes the disease overview and Chronic Cough treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
